EUVIMED · CrossrefZeitschrift
Nature Reviews Drug Discovery
ISSN 1474-1776 · Springer Science and Business Media LLC
Neueste Artikel
First factor XIa inhibitor nabs FDA approval for stroke prevention
The expansion of kinase drug discovery: new targets, platforms and indications
Conditional biologics in cancer immunotherapy: mechanisms, applications and clinical progress
Histone lysine demethylases in the third decade: biology and therapeutic prospects
Decision quality in biopharma portfolio renewal
Regulatory lessons from FDA review of approved AAV gene therapies
Degraders take on GPCRs
Checkpoint inhibitor combinations: the trial-to-approval gap
Linking kinase inhibitors for greater selectivity
FDA approves plasmid DNA-based immunotherapy for rare viral disease
Unlocking biological barriers: nonclinical safety considerations for RNA-based complex biologics
Time to peak sales: how long is the climb?
Filling the massive AI drug discovery data gap
Selective oestrogen receptor degrader class grows with new cancer approval
First myostatin-targeted antibody approved for spinal muscular atrophy
Suppressor tRNA rescues cystic fibrosis
Targeting norovirus RNA structures
Navigating ultralarge virtual screening
Covalent BAX inhibitor confers cytoprotection
Drug conjugate allows cell surface payload release
Psychedelic protects against chemotherapy-induced nerve damage
Gene therapy for rare lysosomal storage disorder nabs FDA approval
Probing the many benefits of GLP-1 receptor agonists
COPD trial wins spur broad respiratory hopes
Molecular glue targets ALK resistance
FDA new drug approvals in Q3 2026
Artificial intelligence in drug discovery — what it is, where we stand and the path forward
Towards precision psychiatry: initial foundations and future directions
Targeting CDKs in the RNAPII transcription cycle
Two trials or not two trials? That should not be the question
EUVIMED